J9229 Injection inotuzumab ozogam 0.1 milligrams
Also known as: inotuzumab ozogamicin, Besponsa
Intravenous injection of inotuzumab ozogamicin, a monoclonal antibody-drug conjugate targeting CD22, dosed per 0.1 milligram.
In Plain Language
acute leukemia-targeting antibody; cancer cell-killing injection
Clinical Context
Used for relapsed or refractory B-cell acute lymphoblastic leukemia.
RVU Information
CPT J9229 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J9229?
CPT J9229 (Injection inotuzumab ozogam 0.1 milligrams) is a J Codes (Drugs) code. Intravenous injection of inotuzumab ozogamicin, a monoclonal antibody-drug conjugate targeting CD22, dosed per 0.1 milligram.
How is J9229 administered?
CPT J9229 is administered by a healthcare provider, typically via injection or infusion. Used for relapsed or refractory B-cell acute lymphoblastic leukemia. It is used by Hematology/Oncology, Medical Oncology.
When is CPT J9229 used?
Used for relapsed or refractory B-cell acute lymphoblastic leukemia.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.